Skip to main content

Advertisement

SpringerLink
Log in

Infliximab for Crohn’s Disease: The First 500 Patients Followed Up Through 2009

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

The aim of this study was to assess the long-term usage patterns and safety of infliximab in patients with Crohn’s disease in clinical practice.

Methods

The medical records of 492 unselected patients treated with infliximab at Mayo Clinic were reviewed and abstracted for demographic features, usage patterns, and adverse events.

Results

The patients received a median of seven infusions and had a median follow-up of 6.3 years. Twenty-eight patients (6 %) were lost to follow-up, 63 patients (13 %) had no clinical benefit, and 401 patients (80 %) had partial or complete response. Of the responding patients, 114 (28 %) received induction treatment only, 167 (42 %) received initial episodic treatment (62 switched to scheduled maintenance treatment of whom 32 [42 %] were still on infliximab at last follow-up), and 120 (30 %) received scheduled maintenance treatment (56 patients [32 %] still on infliximab at last follow-up). Three patients (0.6 %) developed septic shock and six patients (1.5 %) developed septicemia. One patient (0.2 %) developed Mycobacterium avium complex. Histoplasmosis occurred in three patients (0.6 %). The cumulative 10-year probability for developing cancer after infliximab was 9 %. Among the 31 patients developing malignancies (6 %), 15 (3 %) had solid tumors, 11 (2 %) had melanoma and non-melanoma skin cancers, three (0.6 %) had lymphomas (0.6 %), and two (0.4 %) had leukemia. Overall 10-year survival after the final course of infliximab was 94 %. Among the 28 deaths (6 %), nine occurred within 12 weeks of an infliximab infusion—two of these deaths were due to infections.

Conclusions

Long-term follow-up of patients with Crohn’s disease who were treated with infliximab initially between 1998 and 2002 showed persistence of therapy (due to clinical benefit) and an acceptable safety profile, despite the fact that less than one-third initially received three-dose induction followed by scheduled maintenance therapy. Infections and malignancy occurred at rates similar to those previously reported.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–1657.

    Article  PubMed  CAS  Google Scholar 

  2. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s disease cA2 study group. N Engl J Med. 1997;337:1029–1035.

    Article  PubMed  CAS  Google Scholar 

  3. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–1405.

    Article  PubMed  CAS  Google Scholar 

  4. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.

    Article  PubMed  CAS  Google Scholar 

  5. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–885.

    Article  PubMed  CAS  Google Scholar 

  6. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent. N Engl J Med. 2001;345:1098–1104.

    Article  PubMed  CAS  Google Scholar 

  7. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565–2570.

    Article  PubMed  CAS  Google Scholar 

  8. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the food and drug administration. Arthritis Rheum. 2002;46:3151–3158.

    Article  PubMed  CAS  Google Scholar 

  9. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874–881.

    Article  PubMed  CAS  Google Scholar 

  10. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265–267.

    Article  PubMed  Google Scholar 

  11. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol. 2000;95:3490–3497.

    Article  PubMed  CAS  Google Scholar 

  12. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn’s disease: first anniversary clinical experience. Am J Gastroenterol. 2000;95:3469–3477.

    Article  PubMed  CAS  Google Scholar 

  13. Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol. 2001;96:722–729.

    Article  PubMed  CAS  Google Scholar 

  14. Arnott ID, McDonald D, Williams A, et al. Clinical use of infliximab in Crohn’s disease: the Edinburgh experience. Aliment Pharmacol Ther. 2001;15:1639–1646.

    Article  PubMed  CAS  Google Scholar 

  15. Hommes DW, van de Heisteeg BH, van der Spek M, et al. Infliximab treatment for Crohn’s disease: one-year experience in a Dutch academic hospital. Inflamm Bowel Dis. 2002;8:81–86.

    Article  PubMed  Google Scholar 

  16. Sample C, Bailey RJ, Todoruk D, et al. Clinical experience with infliximab for Crohn’s disease: the first 100 patients in Edmonton, Alberta. Can J Gastroenterol. 2002;16:165–170.

    PubMed  Google Scholar 

  17. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19–31.

    Article  PubMed  CAS  Google Scholar 

  18. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut. 2009;58:492–500.

    Article  PubMed  CAS  Google Scholar 

  19. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501–508.

    Article  PubMed  CAS  Google Scholar 

  20. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–35.

    Article  PubMed  CAS  Google Scholar 

  21. Biancone L, Petruzziello C, Orlando A, et al. Cancer in Crohn’s disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis. 2011;17:758–766.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

WJ Sandborn, J-F Colombel, and EV Loftus have served as consultants for Janssen Biotech. WJ Sandborn, J-F Colombel, and EV Loftus have received research support from Janssen Biotech.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street, S.W., Rochester, MN, 55905, USA

    Jennifer L. Seminerio, Edward V. Loftus Jr. & William J. Sandborn

  2. Universite Lille Nord de France et CHU Lille, Lille, France

    Jean-Frédéric Colombel

  3. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA

    Prabin Thapa

  4. Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA

    William J. Sandborn

Authors
  1. Jennifer L. Seminerio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward V. Loftus Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean-Frédéric Colombel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prabin Thapa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. William J. Sandborn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward V. Loftus Jr..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seminerio, J.L., Loftus, E.V., Colombel, JF. et al. Infliximab for Crohn’s Disease: The First 500 Patients Followed Up Through 2009. Dig Dis Sci 58, 797–806 (2013). https://doi.org/10.1007/s10620-012-2405-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-012-2405-z

Keywords

Search

Navigation